Read Why Imara Shares Are Falling Today
Imara Inc (NASDAQ:IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia. Data from the sickle cell disease study interim analysis demonstrated that tovinontrine was generally well-tolerated. Four (3.6%) participants discontinued before week 24 due…
Benzinga ·
Benzinga
